Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Final Results for the year ended December 31, 2019

Faron Pharmaceuticals Oy ("Faron" or the "Company")   Financial statement release January 1 to December 31, 2019   Financial statement release, Turku, 20 March 2019 at 9.00 AM (EET) Inside information   TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today reports its financial statements for the year ended 31 December 2019 and H2 2019.   HIGHLIGHTS   Operational (including post period):   Clevegen[®] - Regulator of major inhibitory immune checkpoints and wholly-owned novel

Limitations to production in Antwerp, Belgium

Stockholm, Sweden, March 20, 2020: Due to new regulations from the Belgian government Atlas Copco’s production in Antwerp, Belgium is affected. A large part of the final assembly is temporarily stopped, while the compressor element production and the distribution center continue to operate. In total 900 out of 1400 employees will be temporarily unemployed from March 23 until April 2.Airpower in Belgium is Atlas Copco’s largest production site and manufactures mostly industrial and portable compressors.     At least 50% of the workforce in the distribution center and the compressor

Castellum stands on stable ground

Due to the prevailing situation on the stock market, Castellum has been flooded with questions from investors and market players which we unfortunately, owing to volatile circumstances, do not have the possibility to answer in full. We would therefore like to transmit this comprehensive fact commentary out to the equities market.The stock market’s pricing of the Castellum share is currently SEK 151, indicating at this time of writing that Castellum is now valued at approx. 77% of its long-range Net Asset Value at last yearend and that the yield amounts to 4.3%, based on the 2019 dividend of

Notice of Annual General Meeting in Bravida Holding AB (publ)

The shareholders in Bravida Holding AB (publ), reg. no. 556891-5390, are summoned to the annual general meeting to be held on Friday 24 April 2020, at 1.00 pm at the company’s offices on Mikrofonvägen 28, Hägersten, Sweden. Registration starts at 12.30 pm.Due to the current pandemic (COVID-19), Bravida Holding AB (publ) has taken a number of precautionary measures ahead of the annual general meeting aimed at keeping the meeting short and efficient and reduce the risk of spreading the virus. No food or drinks will be served before or after the annual general meeting. Bravida Holding AB (publ)

Caverion to be responsible for technical maintenance services for buildings at Stora Enso's Mill in Varkaus, Finland

Caverion Corporation Investor news 20 March 2020 at 09:00 a.m. EETCaverion to be responsible for technical maintenance services for buildings at Stora Enso's Mill in Varkaus, Finland Caverion has signed an agreement with Stora Enso Oyj and Efora Oy on the provision of services for the buildings at Stora Enso’s Varkaus Mill. The service agreement involves a transfer of business whereby the persons working in these activities will be transferred from Stora Enso and Efora to Caverion Suomi Oy as so-called old employees.  Caverion is responsible for the technical maintenance

Vicore informs on clinical programs in relation to the current outbreak of COVID-19

Gothenburg, March 20, 2020 – Vicore Pharma informs on clinical programs in relation to the current outbreak of COVID-19.The on-going clinical study of Raynaud’s phenomenon in patients with systemic sclerosis, in which effects of C21 on blood flow are being studied, has recruited faster than planned. However the clinical trial work will now slow down by trial participants avoiding non-essential hospital visits. “Ensuring safety of trial participants is paramount and based on the performance so far I believe we will be able to swiftly catch up and still report the results by the end of the

New Stirling laboratory in Gothenburg

Swedish Stirling AB has built a new laboratory and test centre for Stirling engines in Gothenburg. The facility, which is now ready for commissioning, will greatly strengthen the company's research and development capacity. The inauguration and demonstration of the facility will be timed depending on the development of the Covid-19 outbreak.[CEO Gunnar Larsson and technician Filip Franzn in Swedish Stirlings new Stirling laboratory]   During the winter, Swedish clean tech company Swedish Stirling built a brand new laboratory and test centre for Stirling engines. The facility, located

Northmill Group AB (publ) repurchases additional Bonds

Northmill Group AB (publ) (“Northmill Group” or “the Company”) has repurchased additional bonds with a nominal value of SEK 85,000,000. The repurchases concern the Company’s senior unsecured bonds with a nominal outstanding amount of SEK 500,000,000 (ISIN:SE0011614973). The bonds have a floating rate corresponding to STIBOR 3m plus 8.0 percent and are due in September 2021. The average purchase price corresponds to 98.58 percent of the nominal value of the bonds.The purpose of the repurchase is to improve Northmill Group’s net interest income. The repurchases have been made possible by

Increase in the number of shares registered in the trade register

Relais Group Plc Company Release 20 March 2020 at 9.00 a.m. EETTotal of 606,250 share subscriptions based on the directed share issue approved by the Board of Directors of Relais Group Plc on 6 February 2020, have been entered into the trade register today. The subscription price for the shares was EUR 8.6091 per share. The directed issue is related to the acquisition of TD Tunga Delar Sverige AB announced on 6 February 2020. With the closing of the acquisition, Relais Group Plc paid SEK 55.0 million of the purchase price by issuing a total of 606,250 new Relais Group Plc's shares to be

Wulff adjusts its outlook for 2020

STOCK EXCHANGE RELEASE March 20, 2020 at 9:00 A.M.   Wulff adjusts its outlook 2020 due to corona virus COVID-19 and preparations arising from it. Based on the Group management’s outlook, it is likely that the comparable operating profit will decrease from year 2019, which was EUR 1.7 million. Earlier the company estimated in its financial statements release on February 17, 2020, that the comparable operating profit will grow from year 2019.   Wulff Group Plc CEO Elina Pienimäki: “Due to corona virus and uncertainties in the global economy we estimate that the comparable

SBB initiates a collaboration with Stockholms Stadsmission to help mitigate the consequences of the COVID-19 crisis

Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") initiates a collaboration with the charity Stockholms Stadsmission to help mitigate the consequences of the COVID-19 crisis. SBB will finance the purchase of food from various restaurants in Stockholm, which will then be donated to Stockholms Stadsmission that helps people in need in our city. Stockholms Stadsmission is the initial beneficiary and the food will be delivered to their operations for the elderly in St Paul. Through this initiative, SBB helps to mitigate negative consequences for some of the groups affected by the COVID-19

Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program

STOCKHOLM — March 20, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronavirus (COVID-19) pandemic. Most importantly, the pivotal phase 2 HORIZON study will not be affected and FDA submission plans are on track for a filing late Q2. The phase 3 OCEAN study with 423 out of 450 planned patients enrolled will remain open for patient enrolment. Topline results are expected to be only slightly delayed. Recruitment for other ongoing clinical studies will be put on temporary pause for patient safety

Orkla ASA: The nomination committee’s recommendation to the General Meeting of Orkla ASA

The Nomination Committee of Orkla ASA has submitted its recommendation regarding the election of shareholder-elected members and a deputy member of the Board of Directors, election of the Chair of the Board of Directors, election of members and the Chair of the Nomination Committee and determination of fees.Please find the recommendation enclosed.  Orkla ASAOslo, 20 March 2020 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

ContextVision – Mandatory notification of trade – primary insider

STOCKHOLM – March 20, 2020 – Monsun AS, controlled by Magne Jordanger, member of the board of ContextVision, has on March 19, 2020 purchased 49 250 shares in ContextVision AB at an average price of NOK 67,27 per share. After the transaction, Monsun AS holds a total of 2 298 000 shares in ContextVision AB. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com. ### About ContextVision ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. As the

Orkla ASA: Orkla’s Annual Report 2019

Orkla's Annual Report for 2019, which also comprises Orkla’s sustainability report, is published today.The Annual Report is only available online. A compressed pdf version of the report is attached. The report is also available on Orkla’s website. Orkla ASAOslo, 20 March 2020Ref.:Group Director Corporate Communications and Corporate Affairs Håkon MageliTel.: +47 928 45 828Email: hakon.mageli@orkla.no VP Investor RelationsElise HeidenreichTel.: +47 951 41 147Email: elise.andersen.heidenreich@orkla.no This information is subject to the disclosure requirements

Redeye: Smart Eye - All Hail the King of DMS

Redeye raises long-term estimates and valuation following breaking news about no less than four new contracts, the composition of which is extremely attractive, in our view. Read more and download the research update: https://bit.ly/2J5g5Bi Start following companies at Redeye to receive the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Q&A related to the impact of the Coronavirus (COVID-19) outbreak on CapMan

CapMan Press Release20 March 2020 at 8:30 a.m. Q&A related to the impact of the Coronavirus (COVID-19) outbreak on CapMan CapMan has published questions and answers (Q&A) related to the impact of the ongoing Coronavirus (COVID-19) outbreak on CapMan. The Q&A is available on the Company’s website www.capman.com/coronavirus-faq/. The company updates the Q&A as the situation develops. For additional information, please contact:Linda Tierala, Director, Communications & IR, CapMan Plc, tel. +358 40 571 7895   About CapManCapMan is a leading Nordic private asset expert with

Gasum delivers biogas to cleantech company Forchem

The energy company Gasum has entered into an agreement with the cleantech company Forchem Oy on the supply of liquefied biogas (LBG) for the Forchem tall oil biorefinery in Rauma, Finland. Forchem switched to using liquefied natural gas (LNG) in 2019.Forchem supplies products for global actors operating in many different markets. The company’s operations are characterized by the principles of sustainable development and minimized environmental impacts. The liquefied biogas (LBG) is received at the Forchem reception terminal, vaporized and used in the company’s production processes. The

Change of venue of the Elisa Annual General Meeting 2 April 2020 and special arrangements

ELISA STOCK EXCHANGE RELEASE 20 MARCH 2020 AT 8:00 AMElisa takes the coronavirus (COVID-19) situation extremely seriously. The Board of Directors of Elisa have decided that the Annual General Meeting on 2 April 2020 will take place if the meeting can be arranged within the restrictions set by authorities. In these circumstances the venue of the Annual General Meeting will be changed from Messukeskus to Elisa's headquarters (Ratavartijankatu 5, Helsinki), and Elisa will contact the participants beforehand. The aim of these measures is to achieve resolutions from the AGM, and ensure

Mandatory notification of trade

On March 19, 2020, Lill Beate Pedersen purchased 14,000 shares in Atea ASA at an average price of NOK 71.08. Lill Beate Pedersen is the CFO for Atea Norway. After purchasing the shares, Pedersen holds 22,800 shares and 60,000 share options in Atea ASA.   For further information, please contact:Robert Giori, CFO Atea ASA, mobile +47 934 09 188Ole Johan Fjellestad, Group Chief Accountant, mobile +47 992 74 829  About AteaAtea is the leading supplier of IT infrastructure and system integration in the Nordic and Baltic regions with more than 7,500 employees. Atea is present in

ZUTEC ANNOUNCES RESIGNATION OF CFO

Zutec Holding AB (publ) (“Zutec") today announced that CFO Clíona Farrelly has tendered her resignation with immediate effect to pursue other career opportunities. She will continue to support the Company during a transition period.   Gustave Geisendorf, CEO of Zutec, says “I would like to thank Clíona for her work during a challenging phase in Zutec’s history and I wish her every success in her future endeavours.”   For more information, please contact:   Gustave Geisendorf, CEO at Zutec gustave.geisendorf@zutec.com, +353 1 201 3565   About Zutec   Zutec

Impact of corona virus (COVID-19) on Targovax’s operations

Oslo, Norway, 20 March 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, issues an update to its investors and analysts. Targovax is running clinical trials at several hospitals both in Europe and the US. Targovax management is following the COVID-19 outbreak situation closely and is continuously working to find mitigating solutions as the situation continues. In the short term there are no significant implications to our core operations. Following the outbreak of COVID-19, authorities on both

Filo Mining Reports 2019 Results and Provides Statement on Readiness and Response to COVID-19

VANCOUVER, March 19, 2020 /CNW/ - Filo Mining Corp. (TSXV: FIL) (Nasdaq First North Growth Market: FIL) ("Filo Mining" or the "Company") is pleased to announce its results for the year ended December 31, 2019.  HIGHLIGHTS 2019 proved to be another pivotal year for the Company as it continued to unlock value at the 100% owned Filo del Sol Project (the “Project”) through ongoing exploration success while also effectively demonstrating the positive economic potential of the Project’s current Mineral Resource through completion of a pre-feasibility study (“PFS”). These two key

Brazilian digital health tech start-up, VivaBem, partners with Sweden’s leading telemedicine provider Doktor.se, and raises USD 2.5 million to expand its digital primary care services in Brazil

VivaBem today announces that it has closed a USD 2.5 million seed investment round led by Swedish investment company Webrock Ventures. Ian Bonde, CEO VivaBem and Joakim Pops, CEO Webrock Ventures   The raise will enable VivaBem to further deliver on its product innovation by integrating Doktor.se’s cutting-edge, AI-driven, technology  within digital healthcare, and ramp up hiring as it gears up for further expansion in the Brazilian market. VivaBem will use the investment to advance its user experience for telemedicine, chronic care management, and health and wellness

There are no items matching the current filter
There are no more items matching the current filter
Back to top